NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5404.50 -97.00 (-1.76%)

65,940 NSE+BSE Volume

NSE 22 May, 2026 3:31 PM (IST)

64,618.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Alkem Laboratories is on 28 May 2026 for the purpose of Audited Results & Final Dividend See details

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

18 Feb 2026

5404.50

-1.76%

Expanding scope of business in the Medtech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Lab (ALKEM) is advancing its MedTech strategy through the acquisition of up to a 55% stake in Occlutech for ~EUR99m (~INR10.6b), gaining control of a specialist in minimally invasive devices for congenital heart disease, stroke prevention, and heart failure.

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

15 Feb 2026

5404.50

-1.76%

Alkem Labs (HOLD): Ex - US international segment performing strongly

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 1.3%/2.4% and -3.4% below our estimates. EBITDA margin reported 25bps lower than estimates at 22.2%

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

15 Feb 2026

5404.50

-1.76%

Temporary pause in India; new venture scale-up on cards

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) reported decent numbers in Q3FY26 led by its international operations. Domestic biz growth slowed to 5.6% YoY, hit by inventory stocking last year and deceleration in trade generics. Management is confident of posting double-digit growth in FY26 (9MFY26 growth at ~10%).

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

14 Feb 2026

5404.50

-1.76%

Acquisition of Occlutech to open opportunities in Med-tech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM is taking significant steps in its Medtech journey through acquiring Occlutech (develops, manufactures, and commercialized medical devices for congenital heart disease, stroke prevention and heart failure).

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

14 Nov 2025

5404.50

-1.76%

Alkem Labs (HOLD): Earnings Beat; increased EBITDA margin guidance

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 9%/9% and 2.8% above our estimates. EBITDA margin reported in line with our estimates at 23%

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

14 Nov 2025

5404.50

-1.76%

Traction across segments scaling margins to newer highs

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) delivered a strong Q2FY26 result led by traction across regions. Growth in India biz (+12% YoY) was led by better traction in chronic therapies and recent foray in medical devices segment, while new launches including gEntresto boosted US revenue (+28%).

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

13 Nov 2025

5404.50

-1.76%

Opex from CDMO/Med-tech to constrain margin expansion over the near term

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM Laboratories (ALKEM) delivered better-than-expected revenue/EBITDA/PAT, with a beat of 6%/9%/13% for the quarter. The superior performance was driven by broad-based higher revenue growth and lower-than-expected R&D spend for the quarter.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

19 Sep 2025

5404.50

-1.76%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Number of FII/FPI investors decreased from 613 to 607 in Mar 2026 qtr

Alkem Laboratories Ltd.

13 Aug 2025

5404.50

-1.76%

Alkem Labs (HOLD): Earnings above expectations, valuations attractive

Hold: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT surpassed our estimates by 4%27%/46%. This was due to lower other expenses & lower ETR

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

13 Aug 2025

5404.50

-1.76%

Strong show; growth outlook improving

Buy: Alkem Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q1FY26 performance exceeded our expectations on all fronts. The outperformance was led by a strong showing in India (up 12%) and improved momentum across US (+8.8%) and other international markets (+9%).

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Is Alkem Laboratories Ltd. worth buying?

141 Votes:

Buy 79.43%

Sell 14.18%

Hold 6.38%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf